ABCG2 and cancer: Interestingly, like nilotinib, sitravatinib is also a TKI that re-sensitizes ABCB1- and ABCG2-overexpressing cancer cells to chemotherapeutic drugs by modulating the drug efflux function of both drug transporters [66,67,68].